Human observational studies link venous thromboembolism with higher mortality, including in middle-aged patients with non-small-cell lung cancer. Frailty, accelerated PhenoAge and clonal hematopoiesis are associated with higher thromboembolism risk, while obesity associations differ across populations. Human trials show no clear effect of cocoa extract, multivitamin-multimineral supplementation or vitamin D plus calcium on thromboembolism.
180 findings in 126 papers from 2005 to 2026, 50 of them since April 2026
“the risk of VTE occurrence reduced by 18% (odds ratio [OR], 0.82 [95% CI, 0.80-0.83]) in participants with overweight”
GLP-1 receptor agonists were not clearly linked with venous thromboembolism in humans (Type 2 diabetes and HR+/HER2-negative metastatic breast cancer receiving CDK4/6 inhibitors) (HR 0.65, 95% CI 0.39-1.09).
HumansType 2 diabetes and HR+/HER2-negative metastatic breast cancer receiving CDK4/6 inhibitors5 yearsfemales
GLP-1 receptor agonists are linked with lower venous thromboembolism in humans (preoperative use before nephrectomy; propensity-matched cohort) (OR 0.62).
Humanspreoperative use before nephrectomy; propensity-matched cohort90 days
Hormone replacement therapy was not clearly linked with venous thromboembolism in humans (Free of baseline ASCVD, VTE, and cancer; initiation compared with non-initiation) (Adjusted HR 1.01, 95% CI 0.82–1.24).
HumansFree of baseline ASCVD, VTE, and cancer; initiation compared with non-initiationPredominantly contemporary oral and transdermal formulationsMean follow-up 12 years; up to 23 yearsfemalesn = 52,330
Estrogen hormone replacement therapy was not clearly linked with venous thromboembolism in humans (postmenopausal patients undergoing breast surgery and reconstruction).
Humanspostmenopausal patients undergoing breast surgery and reconstructionsystemicbreast90 days postoperatively
Perioperative hormone replacement therapy continuation showed no clear effect on venous thromboembolism in humans (perioperative continuation versus cessation).
Vitamin D3 + calcium carbonate showed no clear effect on venous thromboembolism in humans (secondary analysis of RCT) (320 vs 348 VTE events; HR 0.92, 95 % CI 0.79-1.07).
Human trialsecondary analysis of RCToral1,000 mg calcium carbonate + 400 IU vitamin D3 per dayaverage of seven yearsfemalesn = 36,282
Lipoprotein was not clearly linked with venous thromboembolism in humans (High versus low lipoprotein(a) concentrations in Black and White individuals).
HumansHigh versus low lipoprotein(a) concentrations in Black and White individuals
Hormone replacement therapy raises the risk of venous thromboembolism in humans (as reported by the Women's Health Initiative randomised placebo-controlled trial).
Reviewas reported by the Women's Health Initiative randomised placebo-controlled trialfemales
Frailty is linked with a higher risk of venous thromboembolism in humans after transsphenoidal surgery for Cushing disease (8% vs 0.5% and 2.7%, P = .04).
Humansafter transsphenoidal surgery for Cushing disease
GLP-1 receptor agonists are linked with a lower risk of venous thromboembolism in humans (adults with obesity and autoimmune disease; propensity-matched target trial emulation) (HR 0.83 (95% CI 0.72-0.95)).
Humansadults with obesity and autoimmune disease; propensity-matched target trial emulation
GLP-1 receptor agonists are associated with venous thromboembolism in humans Following Achilles tendon repair in obese patients (2.6% vs. 6.4%; p = 0.5; not statistically significant).
HumansFollowing Achilles tendon repair in obese patientsn = 337
Venous thromboembolism is linked with higher mortality, while frailty and accelerated PhenoAge are linked with higher thromboembolism risk in human studies. Obesity associations differ by population: lower risk in at-risk inpatients but higher risk in internal medical inpatients. A human trial finds no clear effect of multivitamin-multimineral supplements or cocoa extract.
Summary rewritten as its findings changed.
As it read before
Venous thromboembolism is associated with higher mortality in human cohorts; frailty, PhenoAge acceleration and clonal hematopoiesis of indeterminate potential are linked with higher thromboembolism risk. Obesity is linked with lower risk in at-risk inpatients but higher risk in internal medical inpatients. Human trials show no clear effect of multivitamin-mineral supplements or cocoa extract, or vitamin D3 plus calcium in women.
Summary rewritten as its findings changed.
As it read before
Frailty, PhenoAge acceleration and clonal hematopoiesis are associated with higher venous thromboembolism risk in human cohorts. Obesity is linked with higher risk in internal medical inpatients but lower risk in broader at-risk inpatient populations. A human trial shows no clear effect of cocoa extract or multivitamin-multimineral supplementation on venous thromboembolism.
Human cohorts link frailty, higher PhenoAgeAccel, and clonal hematopoiesis with greater venous thromboembolism risk. Obesity is linked with lower risk among at-risk inpatients but higher risk among internal medical inpatients. Human trials report no clear effect from multivitamin-multimineral supplements or cocoa extract, or from vitamin D3 plus calcium carbonate in women.
Summary rewritten as its findings changed.
As it read before
Human cohorts link frailty, PhenoAge acceleration, and clonal hematopoiesis of indeterminate potential with higher venous thromboembolism risk, while greater cardiorespiratory fitness is associated with lower risk. Obesity is linked with lower risk in at-risk inpatients but higher risk in internal medicine inpatients. A human trial reports no clear effect of cocoa extract or multivitamin-multimineral supplementation on venous thromboembolism.
The pattern appeared in 28.7% of glucocorticoid users and involved reduced clot breakdown and injury to the protective coating inside blood vessels.The pattern appeared in 28.7% of glucocorticoid users and involved reduced clot breakdown and injury to the protective coating inside blood vessels.
Higher grip strength relative to body weight was linked to 13% lower relative clot risk per standard deviation, a measure of variation in strength.Higher grip strength relative to body weight was linked to 13% lower relative clot risk per standard deviation, a measure of variation in strength.
An observational genomic analysis linked 25 of 31 menopause-relevant DNA variants to at least one trait, with associations spanning up to 16 traits per variant.An observational genomic analysis linked 25 of 31 menopause-relevant DNA variants to at least one trait, with associations spanning up to 16 traits per variant.
Over 10 years, 1.6% of hormone therapy users died versus 1.7% of nonusers; hospitalization, worsening heart failure and blood-clot hazards were higher among users.Over 10 years, 1.6% of hormone therapy users died versus 1.7% of nonusers; hospitalization, worsening heart failure and blood-clot hazards were higher among users.